Classifying antipsychotic agents: Need for new terminology

CNS Drugs

Volumn 22, Issue 12, 2008, Pages 1047-1059

  Jindal, Ripu D ^a   Keshavan, Matcheri S ^b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Antipsychotics, adverse reactions; Antipsychotics, pharmacodynamics; Antipsychotics, therapeutic use; Cognitive function; Diabetes mellitus, drug induced; Extrapyramidal disorders, drug induced; Hyperprolactinaemia, drug induced

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMISULPRIDE; AMOXAPINE; ARIPIPRAZOLE; ATROPINE; BIFEPRUNOX; BUNGAROTOXIN RECEPTOR; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; LOXAPINE; MEPYRAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SERTINDOLE; SULPIRIDE; UNINDEXED DRUG; ZIPRASIDONE;

AGRANULOCYTOSIS; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HEART RATE VARIABILITY; HUMAN; HYPERPROLACTINEMIA; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; REVIEW; RISK FACTOR; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COGNITION; DIABETES MELLITUS; DYSKINESIA, DRUG-INDUCED; EXTRAPYRAMIDAL TRACTS; HUMANS; PROLACTIN; RECEPTORS, NEUROTRANSMITTER; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 55949084634     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/0023210-200822120-00007     Document Type: Review

References (105)

1. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUt-LASS 1). Arch Gen Psychiatry 2006 Oct; 63 (10): 1079-87
2. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003 May; 28 (5): 995-1003
3. Cohen D, Stolk RP, Grobbee DE, et al. Hyperglycaemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006 Apr; 29 (4): 786-91
4. Silvestre JS, Prous J. Research on adverse drug events: I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005 Jun; 27 (5): 289-304
5. Jindal RD, Keshavan MS. Critical role of M3 muscarinic receptor in insulin secretion: implications for psychopharmacology. J Clin Psychopharmacol 2006 Oct; 26 (5): 449-50
6. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003 Mar; 28 (3): 519-26
7. Bymaster FP, Felder CC, Tzavara E, et al. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003 Oct; 27 (7): 1125-43
8. Malaspina D, Dalack G, Leitman D, et al. Low heart rate variability is not caused by typical neuroleptics in schizophrenia patients. CNS Spectr 2002 Jan; 7 (1): 53-7
9. Eschweiler GW, Bartels M, Langle G, et al. Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine. Pharmacopsychiatry 2002 May; 35 (3): 96-100
10. Rechlin T, Beck G, Weis M, et al. Correlation between plasma clozapine concentration and heart rate variability in schizophrenic patients. Psychopharmacology (Berl) 1998 Feb; 135 (4): 338-41
11. Hippius H. The history of clozapine. Psychopharmacology (Berl) 1989; 99 Suppl.: S3-5
12. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2007 Mar; 18 (1): 39-60
13. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007 Jul; 164 (7): 1050-60
14. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992 Jul; 49 (7): 538-44
15. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000 Apr; 157 (4): 514-20
16. Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002 Feb; 159 (2): 180-90
17. Kapur S, Cho R, Jones C, et al. Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy. Biol Psychiatry 1999 May 1; 45 (9): 1217-20
18. Apiquian R, Fresan A, Ulloa RE, et al. Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. Neuropsychopharmacology 2005 Dec; 30 (12): 2236-44
19. PDSP Ki database [online]. Available from URL: http://pdsp.cwru.edu/pdsp. php [Accessed 2008 Sep 17]
20. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001 Dec 1; 50 (11): 873-83
21. Agid O, Mamo D, Ginovart N, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response: a double-blind PET study in schizophrenia. Neuropsychopharmacology 2007 Jun; 32 (6): 1209-15
22. Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006 Sep; 31 (9): 1991-2001
23. Silvestri S, Seeman MV, Negrete JC, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000 Oct; 152 (2): 174-80
24. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004 Mar; 161 (3): 414-25
25. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007 Mar; 20 (2): 131-7
26. Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci 2001 Jun; 251 (3): 141-6
27. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997 Jun; 54 (6): 549-57
28. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997 Aug 15; 42 (4): 233-46
29. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006 Jun; 30 (4): 714-7
30. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003 Jul; 60 (7): 681-90
31. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003 Apr; 166 (4): 391-9
32. Inoue T, Domae M, Yamada K, et al. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996 Apr; 277 (1): 137-43
33. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004 Sep; 18 (3): 375-83
34. Gudelsky GA. Tuberoinfundibular dopamine neurons and the regulation of prolactin secretion. Psychoneuroendocrinology 1981; 6 (1): 3-16
35. Kapur S, Roy P, Daskalakis J, et al. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001 Feb; 158 (2): 311-4
36. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002 Sep; 302 (3): 1129-34
37. Jaber M, Robinson SW, Missale C, et al. Dopamine receptors and brain function. Neuropharmacology 1996; 35 (11): 1503-19
38. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000 Dec 2; 321 (7273): 1371-6
39. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003 Jun 1; 60 (6): 553-64
40. Rosenheck RA. Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv 2005 Jan; 56 (1): 85-92
41. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003 Nov 26; 290 (20): 2693-702
42. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006 Feb; 163 (2): 185-94
43. Nuechterlein KH, Barch DM, Gold JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004 Dec 15; 72 (1): 29-39
44. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996 Mar; 153 (3): 321-30
45. Harvey PD. Cognitive and functional effects of atypical antipsychotic medications. J Clin Psychiatry 2006 Oct; 67 (10): e13
46. Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005 Sep; 8 (3): 457-72
47. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004 May 15; 55 (10): 1013-22
48. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007 Jun; 64 (6): 633-47
49. Graham FK. Presidential address, 1974. The more or less startling effects of weak prestimulation. Psychophysiology 1975 May; 12 (3): 238-48
50. Peng RY, Mansbach RS, Braff DL, et al. A D2 dopamine receptor agonist disrupts sensorimotor gating in rats: implications for dopaminergic abnormalities in schizophrenia. Neuropsychopharmacology 1990 Jun; 3 (3): 211-8
51. Swerdlow NR, Braff DL, Taaid N, et al. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994 Feb; 51 (2): 139-54
52. Wan FJ, Taaid N, Swerdlow NR. Do D1/D2 interactions regulate prepulse inhibition in rats? Neuropsychopharmacology 1996 Apr; 14 (4): 265-74
53. Hoffman DC, Donovan H. D1 and D2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia. Psychopharmacology (Berl) 1994 Aug; 115 (4): 447-53
54. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000 Mar 17; 287 (5460): 2020-2
55. Fletcher PJ, Tenn CC, Sinyard J, et al. A sensitizing regimen of amphetamine impairs visual attention in the 5-choice serial reaction time test: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Neuropsychopharmacology 2007 May; 32 (5): 1122-32
56. Reilly JL, Harris MS, Keshavan MS, et al. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry 2006 Nov; 63 (11): 1189-97
57. Reilly JL, Harris MS, Khine TT, et al. Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. Biol Psychiatry 2007 Oct 1; 62 (7): 818-21
58. Williams GV, Rao SG, Goldman-Rakic PS. The physiological role of 5-HT2A receptors in working memory. J Neurosci 2002 Apr 1; 22 (7): 2843-54
59. Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci 2004 Jun; 114 (6): 593-611
60. Ellis JR, Ellis KA, Bartholomeusz CF, et al. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int J Neuropsychopharmacol 2006 Apr; 9 (2): 175-89
61. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006 Jun; 63 (6): 630-8
62. Boess FG, De Vry J, Erb C, et al. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2- (methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 2007 May; 321 (2): 716-25
63. Singhal SK, Zhang L, Morales M, et al. Antipsychotic clozapine inhibits the function of alpha7-nicotinic acetylcholine receptors. Neuropharmacology 2007 Feb; 52 (2): 387-94
64. Pocivavsek A, Icenogle L, Levin ED. Ventral hippocampal alpha7 and alpha4beta2 nicotinic receptor blockade and clozapine effects on memory in female rats. Psychopharmacology (Berl) 2006 Nov; 188 (4): 597-604
65. Thornton AE, Van Snellenberg JX, Sepehry AA, et al. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol 2006 May; 20 (3): 335-46
66. Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002 Jun 15; 51 (12): 972-8
67. Keefe RS, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004 Jun; 161 (6): 985-95
68. Marder SR, Glynn SM, Wirshing WC, et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003 Aug; 160 (8): 1405-12
69. McGurk SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999; 60 Suppl. 12: 24-9
70. Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 2004 Dec; 177 (1-2): 207-16
71. Roegge CS, Perraut C, Hao X, et al. Histamine H1 receptor involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine. Pharmacol Biochem Behav 2007 Apr; 86 (4): 686-92
72. Passani MB, Bacciottini L, Mannaioni PF, et al. Central histaminergic system and cognition. Neurosci Biobehav Rev 2000 Jan; 24 (1): 107-13
73. Bacciottini L, Passani MB, Mannaioni PF, et al. Interactions between histaminergic and cholinergic systems in learning and memory. Behav Brain Res 2001 Oct 15; 124 (2): 183-94
74. Bacciottini L, Passani MB, Giovannelli L, et al. Endogenous histamine in the medial septum-diagonal band complex increases the release of acetylcholine from the hippocampus: a dual-probe microdialysis study in the freely moving rat. Eur J Neurosci 2002 May; 15 (10): 1669-80
75. Giovannini MG, Efoudebe M, Passani MB, et al. Improvement in fear memory by histamine-elicited ERK2 activation in hippocampal CA3 cells. J Neurosci 2003 Oct 8; 23 (27): 9016-23
76. Jones CK, Eberle EL, Shaw DB, et al. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther 2005 Mar; 312 (3): 1055-63
77. Di Cara B, Panayi F, Gobert A, et al. Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats. Int J Neuropsychopharmacol 2007 Jun; 10 (3): 383-99
78. Cassel JC, Jeltsch H. Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Neuroscience 1995 Nov; 69 (1): 1-41
79. Hayashi A, Suzuki M, Sasamata M, et al. Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats. Psychopharmacology (Berl) 2005 Mar; 178 (2-3): 241-9
80. Nonogaki K, Strack AM, Dallman MF, et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 1998 Oct; 4 (10): 1152-6
81. Miller KJ. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Mol Interv 2005 Oct; 5 (5): 282-91
82. Yuan X, Yamada K, Ishiyama-Shigemoto S, et al. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000 Mar; 43 (3): 373-6
83. Pooley EC, Fairburn CG, Cooper Z, et al. A 5-HT2C receptor promoter polymorphism (HTR2C - 759C/T) is associated with obesity in women, and with resistance to weight loss in heterozygotes. Am J Med Genet B Neuropsychiatr Genet 2004 Apr 1; 126 (1): 124-7
84. Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006 Sep; 7 (6): 863-87
85. Ryu S, Cho EY, Park T, et al. -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007 Apr 13; 31 (3): 673-7
86. Orthen-Gambill N. Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats. Pharmacol Biochem Behav 1988 Sep; 31 (1): 81-6
87. Kim SF, Huang AS, Snowman AM, et al. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007 Feb 27; 104 (9): 3456-9
88. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004 Apr 1; 428 (6982): 569-74
89. Gilon P, Henquin JC. Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocr Rev 2001 Oct; 22 (5): 565-604
90. Gautam D, Han SJ, Hamdan FF, et al. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 2006 Jun; 3 (6): 449-61
91. Johnson DE, Yamazaki H, Ward KM, et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005 May; 54 (5): 1552-8
92. Renuka TR, Robinson R, Paulose CS. Increased insulin secretion by muscarinic M1 and M3 receptor function from rat pancreatic islets in vitro. Neurochem Res 2006 Mar; 31 (3): 313-20
93. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003 May; 111 (5): S835-42
94. Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology 2007 Dec; 32 (12): 2561-9
95. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006 Dec 14; 444 (7121): 840-6
96. Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Diabetes. Diabetes Care 2004 Feb; 27 (2): 596-601
97. Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006 Dec; 88 (1-3): 63-72
98. Mulsant BH, Gharabawi GM, Bossie CA, et al. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry 2004 Dec; 65 (12): 1708-14
99. Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther 2007 Feb; 81 (2): 235-41
100. Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006 Feb 25; 332 (7539): 455-9
101. Ayer A, Antic V, Dulloo AG, et al. Hemodynamic consequences of chronic parasympathetic blockade with a peripheral muscarinic antagonist. Am J Physiol Heart Circ Physiol 2007 Aug; 293 (2): H1265-72
102. Mizrahi R, Rusjan P, Agid O, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 2007 Apr; 164 (4): 630-7
103. Nicholson AN, Pascoe PA, Turner C, et al. Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 1991 Sep; 104 (1): 270-6
104. Passani MB, Giannoni P, Bucherelli C, et al. Histamine in the brain: beyond sleep and memory. Biochem Pharmacol 2007 Apr 15; 73 (8): 1113-22
105. Sica DA. Alpha1-adrenergic blockers: current usage considerations. J Clin Hypertens (Greenwich) 2005 Dec; 7 (12): 757-62